{"id":390055,"date":"2021-04-01T00:00:00","date_gmt":"2021-04-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0011-2020-biopharma-ovarian-cancer-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-05-05T11:20:59","modified_gmt":"2026-05-05T11:20:59","slug":"dlsfon0011-2020-biopharma-ovarian-cancer-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0011-2020-biopharma-ovarian-cancer-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Ovarian Cancer | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche\/Genentech\/Chugai\u2019s Avastin and three PARP inhibitors (AstraZeneca \/ Merck Sharp &#038; Dohme\u2019s Lynparza, Clovis Oncology\u2019s Rubraca, and GlaxoSmithKline \/ Tesaro\u2019s Zejula), treatment is moving toward a targeted approach. Multiple combination therapies incorporating immune checkpoint inhibitors are in late-phase development for ovarian cancer, and we anticipate that this drug class will significantly change the treatment of this disease.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What is the size of the drug-treatable ovarian cancer population, and how will the drug-treatment rates change over time?<\/li>\n<li>What is the current state of treatment in ovarian cancer? Which drugs are the most important? What are interviewed experts\u2019 insights on current treatment options? What are the main unmet needs in the treatment of ovarian cancer?<\/li>\n<li>What are the most promising agents in the pipeline, and how will they shape the future of the ovarian cancer market? What notable therapies are progressing in early-phase trials?<\/li>\n<li>What is the expected impact of the approvals of Roche \/ Genentech \/Chugai\u2019s Tecentriq, GlaxoSmithKline \/ Tesaro\u2019s dostarlimab, AstraZeneca\u2019s Imfinzi, Bristol Myers Squibb \/ Ono Pharmaceutical\u2019s Opdivo, and Merck Sharp &#038; Dohme\u2019s Keytruda on the ovarian cancer market? What competition will other drug classes present to immune checkpoint inhibitors?<\/li>\n<li>What are the drivers and constraints in the ovarian cancer market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:<\/strong> More than 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>Key companies:<\/strong> Roche \/ Genentech, GlaxoSmithKline \/ Tesaro, Clovis Oncology, AstraZeneca, AbbVie, Merck KGaA, Pfizer, Bristol Myers Squibb, Merck &#038; Co., ImmunoGen, Sotio, VBL Therapeutics, Novartis.<\/p>\n<p><strong>Key drugs:<\/strong> Avastin (bevacizumab), Lynparza (olaparib), Zejula (niraparib), Rubraca (rucaparib), Talzenna (talazoparib), Opdivo (nivolumab), Bavencio (avelumab), Tecentriq (atezolizumab), Imfinzi (durvalumab), Keytruda (pembrolizumab), Mekinist (trametinib), dostarlimab, mirvetuximab soravtansine, cediranib, ofranergene obadenovec, DCVAC\/OvCa, mirvetuximab soravtansine, oregovomab, AVB-500.<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).<\/p>\n<p><strong>Population segments in market forecast:<\/strong> Early-stage first line, advanced-stage first line, second-line platinum-sensitive, second-line platinum-resistant and -refractory, third-line platinum-sensitive, third-line platinum-resistant and -refractory, and fourth and subsequent lines.<\/p>\n<p><strong>Market forecast features: <\/strong>Ten-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2029, segmented by brands\/generics and epidemiological subpopulations.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast:<\/em> Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390055","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ovarian-cancer","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390055\/revisions"}],"predecessor-version":[{"id":576423,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390055\/revisions\/576423"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}